Erratum: Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum].
[This corrects the article on p. 227 in vol. 8, PMID: 27284260.].